- $13.52m
- $8.01m
- $3.95m
- 27
- 14
- 48
- 19
Annual income statement for Geovax Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.82 | 0.386 | 0.082 | 0 | 3.95 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.64 | 19 | 14.1 | 26.7 | 29.1 |
| Operating Profit | -2.82 | -18.6 | -14 | -26.7 | -25.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.96 | -18.6 | -14 | -26 | -25 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.96 | -18.6 | -14 | -26 | -25 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.96 | -18.6 | -14 | -26 | -25 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.96 | -18.6 | -14 | -26 | -25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -32.1 | -46.1 | -12.4 | -14.3 | -4.82 |